Article
A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival.
Blood - 1 Jun 2005
Alvi Azra J, Austen Belinda, Weston Victoria J, Fegan Christopher, MacCallum David, Gianella-Borradori Athos, Lane David P, Hubank Mike, Powell Judith E, Wei Wenbin, Taylor A Malcolm R, Moss Paul A H, Stankovic Tatjana
Abstract excerpt
B-cell chronic lymphocytic leukemia (B-CLL) is a clinically variable disease where mutations in DNA damage response genes ATM or TP53 affect the response to standard therapeutic agents. The in vitro cytotoxicity of a novel cyclin-dependent kinase inhibitor, CYC202, was evaluated in 26 B-CLLs, 11 with mutations in either the ATM or TP53 genes, and compared with that induced by ionizing radiation and fludarabine....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.